FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 347 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Metformin May Affect Risk of Breast Cancer in Women with Type... January 28, 2021 Man Walks Entire Continent To Spread Awareness About Mental Health &... January 16, 2022 The Cancer Moonshot: Moving from Planning to Research November 19, 2018 GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of... October 1, 2020 Load more HOT NEWS Atlantic rowing trio smash world record and raise thousands for cancer... Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented...
